Cargando…
Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment
INTRODUCTION: Photoimmunotherapy is a breakthrough treatment for malignant tumors. Its uniqueness is that it uses antibody mediated targeted delivery to achieve high tumor specificity and uses laser-activated biophysical mechanism to accurately induce the rapid death of cancer cells and avoid damagi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677922/ https://www.ncbi.nlm.nih.gov/pubmed/36419717 http://dx.doi.org/10.2147/IJN.S373282 |
_version_ | 1784833896210235392 |
---|---|
author | Kong, Cunqing Xu, Banghao Qiu, Guanhua Wei, Meng Zhang, Mengqi Bao, Shengxian Tang, Jiali Li, Lequn Liu, JunJie |
author_facet | Kong, Cunqing Xu, Banghao Qiu, Guanhua Wei, Meng Zhang, Mengqi Bao, Shengxian Tang, Jiali Li, Lequn Liu, JunJie |
author_sort | Kong, Cunqing |
collection | PubMed |
description | INTRODUCTION: Photoimmunotherapy is a breakthrough treatment for malignant tumors. Its uniqueness is that it uses antibody mediated targeted delivery to achieve high tumor specificity and uses laser-activated biophysical mechanism to accurately induce the rapid death of cancer cells and avoid damaging the surrounding normal tissues. METHODS: In this paper, an iron-based micelle was designed to encapsulate the photothermal agent indocyanine green (ICG) and a cyclic tripeptide of arginine-glycine-aspartic acid (cRGD) as targeted multifunctional ICG@SANPs-cRGD nanoparticles for combined photothermal/photodynamic/immune therapy of breast cancer. RESULTS: The experimental results show that ICG@SANPs-cRGD nanoparticles have good biocompatibility and photothermal conversion ability. Photothermal therapy (PTT) and photodynamic therapy (PDT) based on ICG@SANPs-cRGD can not only inhibit the proliferation, invasion and migration of tumor cells, but also directly kill tumor cells by inducing apoptosis or necrosis. Dual-mode fluorescence light (FL) and magnetic resonance imaging (MRI) imaging in mice confirmed the selective accumulation at tumor sites and imaging ability of ICG@SANPs-cRGD. PTT/PDT combined with Anti-PD-L1 immunotherapy based on ICG@SANPs-cRGD mediated the immunogenic cell death (ICD) of tumor cells by regulating the expression of immune-related indicators and activated the body’s immune response mechanism, which enhanced the immunotherapy effect of immune checkpoint block (ICB). PTT/PDT combined with Anti-PD-L1 therapy not only prevented the progression of the primary tumor but also inhibited the distant metastasis of the tumor. DISCUSSION: This study explores the biomedical application of PTT/PDT combined with Anti-PD-L1 based on ICG@SANPs-cRGD nanomaterials for breast cancer treatment and demonstrates the potential of ICG@SANPs-cRGD as a multifunctional therapeutic platform for future cancer therapy. |
format | Online Article Text |
id | pubmed-9677922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-96779222022-11-22 Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment Kong, Cunqing Xu, Banghao Qiu, Guanhua Wei, Meng Zhang, Mengqi Bao, Shengxian Tang, Jiali Li, Lequn Liu, JunJie Int J Nanomedicine Original Research INTRODUCTION: Photoimmunotherapy is a breakthrough treatment for malignant tumors. Its uniqueness is that it uses antibody mediated targeted delivery to achieve high tumor specificity and uses laser-activated biophysical mechanism to accurately induce the rapid death of cancer cells and avoid damaging the surrounding normal tissues. METHODS: In this paper, an iron-based micelle was designed to encapsulate the photothermal agent indocyanine green (ICG) and a cyclic tripeptide of arginine-glycine-aspartic acid (cRGD) as targeted multifunctional ICG@SANPs-cRGD nanoparticles for combined photothermal/photodynamic/immune therapy of breast cancer. RESULTS: The experimental results show that ICG@SANPs-cRGD nanoparticles have good biocompatibility and photothermal conversion ability. Photothermal therapy (PTT) and photodynamic therapy (PDT) based on ICG@SANPs-cRGD can not only inhibit the proliferation, invasion and migration of tumor cells, but also directly kill tumor cells by inducing apoptosis or necrosis. Dual-mode fluorescence light (FL) and magnetic resonance imaging (MRI) imaging in mice confirmed the selective accumulation at tumor sites and imaging ability of ICG@SANPs-cRGD. PTT/PDT combined with Anti-PD-L1 immunotherapy based on ICG@SANPs-cRGD mediated the immunogenic cell death (ICD) of tumor cells by regulating the expression of immune-related indicators and activated the body’s immune response mechanism, which enhanced the immunotherapy effect of immune checkpoint block (ICB). PTT/PDT combined with Anti-PD-L1 therapy not only prevented the progression of the primary tumor but also inhibited the distant metastasis of the tumor. DISCUSSION: This study explores the biomedical application of PTT/PDT combined with Anti-PD-L1 based on ICG@SANPs-cRGD nanomaterials for breast cancer treatment and demonstrates the potential of ICG@SANPs-cRGD as a multifunctional therapeutic platform for future cancer therapy. Dove 2022-11-17 /pmc/articles/PMC9677922/ /pubmed/36419717 http://dx.doi.org/10.2147/IJN.S373282 Text en © 2022 Kong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kong, Cunqing Xu, Banghao Qiu, Guanhua Wei, Meng Zhang, Mengqi Bao, Shengxian Tang, Jiali Li, Lequn Liu, JunJie Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment |
title | Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment |
title_full | Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment |
title_fullStr | Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment |
title_full_unstemmed | Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment |
title_short | Multifunctional Nanoparticles-Mediated PTT/PDT Synergistic Immune Activation and Antitumor Activity Combined with Anti-PD-L1 Immunotherapy for Breast Cancer Treatment |
title_sort | multifunctional nanoparticles-mediated ptt/pdt synergistic immune activation and antitumor activity combined with anti-pd-l1 immunotherapy for breast cancer treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677922/ https://www.ncbi.nlm.nih.gov/pubmed/36419717 http://dx.doi.org/10.2147/IJN.S373282 |
work_keys_str_mv | AT kongcunqing multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT xubanghao multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT qiuguanhua multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT weimeng multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT zhangmengqi multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT baoshengxian multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT tangjiali multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT lilequn multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment AT liujunjie multifunctionalnanoparticlesmediatedpttpdtsynergisticimmuneactivationandantitumoractivitycombinedwithantipdl1immunotherapyforbreastcancertreatment |